First SBL-3 ClearView Multifocal Intraocular Lens Implanted in US

Lenstec announce that the first US commercial implantations of their newly FDA approved SBL-3 ClearView Multifocal IOL (MIOL) were performed by Jeff Whitsett, MD, of Whitsett Vision, Houston, Texas.

The SBL-3 Clearview Multifocal is a next-generation presbyopia-correcting IOL design that in FDA clinical trials provided patients with near, intermediate, and distance vision, with reports of much lower visual disturbances than traditional MIOLs. Additionally, over 90% of patients achieved binocular visual acuities of 20/25 or better at all distances, as well as over 93% reporting spectacle independence.

View the EyewireTV coverage of the FDA approval of the SBL-3 here. 

Dr. Whitsett served as a principal investigator in FDA trials of the ClearView MIOL.

“Patients have reported high levels of satisfaction with minimal side effects. I believe the SBL-3 ClearView MIOL will be an excellent option for refractive lens surgeons," Dr. Whitsett said in a company news release. 

"Lenstec is proud to have a surgeon of Dr Whitsett's caliber be the first to implant our new ClearView MIOL in the US," said Jimmy Chacko, Vice President of Regulatory Affairs at Lenstec. "Years of clinical trial work by him and his staff helped catapult Lenstec into the presbyopia correction arena. We look forward to his continued use and exceptional outcomes for his patients"